Journal of Virology · 2004 · 422 citations · 32 references
Life SciencesImmunologyInfectious DiseasesImmunotherapyVaccinologyVirologyAntiviral ImmunityRespiratory Infectious DiseasesViral InfectionsViral PersistenceViral ReplicationViral VaccinesAntiviral ImmunotherapyCoronavirus VaccinesRespiratory Viral InfectionsRespiratory VirusesSevere Acute Respiratory SyndromeViral Antigen DetectionViral Replication InhibitionViral Respiratory Infections
Following intranasal administration, the severe acute respiratory syndrome (SARS) coronavirus replicated to high titers in the respiratory tracts of BALB/c mice. Peak replication was seen in the absence of disease on day 1 or 2, depending on the dose administered, and the virus was cleared within a week. Viral antigen and nucleic acid were detected in bronchiolar epithelial cells during peak viral replication. Mice developed a neutralizing antibody response and were protected from reinfection 28 days following primary infection. Passive transfer of immune serum to naïve mice prevented virus replication in the lower respiratory tract following intranasal challenge. Thus, antibodies, acting alone, can prevent replication of the SARS coronavirus in the lung, a promising observation for the development of vaccines, immunotherapy, and immunoprophylaxis regimens.
32
A simple method of estimating 50 per cent end points
Hr Muench · Medical Entomology and Zoology · 1938 · 8.4K citations
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Dean D. Erdman, Goldsmith Cs, Zaki et al. · New England Journal of Medicine · 2003 · 4.5K citations